Search

Daicel Corporation Osteoclast Differentiation Inhibitor Urolithin EP3756664A1

The European Patent Office published patent application EP3756664A1 for Daicel Corporation on April 15, 2026, covering osteoclast differentiation inhibitor compositions containing urolithin. The inventors are KOBATA Kenji, NAKATANI Sachie, and KUDOH Masatake. The application is classified under A61K 31/37 (phthalide compounds) with designations covering 32 European states including DE, FR, GB, IT, and NL.

Separating Agent for Human Serum IgG Antibodies

The European Patent Office published application EP3375875A1, a patent for a separating agent for human serum-derived IgG polyclonal antibodies and the method of separation. The applicants are National University Corporation, Kyoto Institute of Technology, and Daicel Corporation. The invention covers IPC classifications C07K, C12N, and C12Q related to immunoglobulin separation.